Preferred Label : Elironrasib;
NCIt synonyms : KRAS-G12C(ON) Inhibitor RMC-6291; KRAS G12C(ON) Inhibitor RMC-6291; KRAS G12C Inhibitor RMC-6291;
NCIt definition : An orally bioavailable, covalent inhibitor of the active, guanosine triphosphate (GTP)-bound
form of the oncogenic KRAS substitution mutation G12C, KRAS G12C(ON), with potential
antineoplastic activity. Upon oral administration, elironrasib forms a tri-complex
with the intracellular chaperone protein and immunophilin cyclophilin A (CypA) and
KRAS G12C(ON). This tri-complex inhibits KRAS G12C(ON)-mediated signaling, which may
inhibit tumor cell proliferation. KRAS, a member of the RAS family of oncogenes, serves
an important role in cell signaling, division and differentiation. Mutations of KRAS
may induce constitutive signal transduction leading to tumor cell growth, proliferation,
invasion, and metastasis.;
UNII : 942KVV5CJP;
CAS number : 2641998-63-0;
Molecule name : RMC-6291; RMC 6291;
NCI Metathesaurus CUI : CL1798653;
Origin ID : C189824;
UMLS CUI : C5706556;
Semantic type(s)
- concept_is_in_subset
- has_target
